WeLeader Biomedical Co., Ltd. (TPEX:7713)
Taiwan · Delayed Price · Currency is TWD 67.20
+0.10 (0.15%)
May 29, 2026, 1:30 PM CST
WeLeader Biomedical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 220.57 | 208.56 | 170.21 | 152.28 | 153.8 | 105.77 |
Depreciation & Amortization | 125.81 | 124.16 | 108.58 | 103.8 | 109.82 | 114.44 |
Loss (Gain) From Sale of Assets | - | - | 0.02 | 1.69 | -0.69 | -0.41 |
Loss (Gain) From Sale of Investments | 0.15 | -0.15 | -0.4 | -0.1 | 0.68 | -0.01 |
Stock-Based Compensation | - | 1.61 | - | 0.18 | 4.23 | 3.65 |
Provision & Write-off of Bad Debts | 0.03 | -0.1 | 0.06 | -0.48 | -0.53 | 0.39 |
Other Operating Activities | 7.91 | -0.59 | -6.84 | -19.56 | 8.41 | 12.49 |
Change in Accounts Receivable | -40.65 | -46.63 | -5.75 | -3.17 | 21.59 | -47.61 |
Change in Inventory | -17.36 | -18.78 | -29.81 | -5.77 | -7.1 | -13.37 |
Change in Accounts Payable | -14.71 | 20.39 | 40.35 | -12.09 | -5.37 | 43.39 |
Change in Unearned Revenue | 3.72 | 3.67 | 1.19 | -0.36 | -1.25 | 1.02 |
Change in Other Net Operating Assets | 15.46 | 21.16 | 1.14 | 15.43 | -3.3 | 18.27 |
Operating Cash Flow | 300.94 | 313.3 | 278.76 | 231.86 | 280.27 | 238.03 |
Operating Cash Flow Growth | 7.24% | 12.39% | 20.23% | -17.27% | 17.75% | - |
Capital Expenditures | -181.93 | -212.74 | -170.71 | -114.73 | -659.36 | -21.6 |
Sale of Property, Plant & Equipment | 1.29 | - | - | 0.95 | 1.06 | 0.42 |
Sale (Purchase) of Intangibles | -1.67 | -1.01 | -3.56 | -1 | -2.29 | -2.3 |
Investment in Securities | -52.31 | -61.66 | -22.39 | 0.83 | -4.68 | 20.77 |
Investing Cash Flow | -234.62 | -275.4 | -196.65 | -113.96 | -665.28 | -2.71 |
Short-Term Debt Issued | - | 80 | 79 | 224 | 247 | 53 |
Long-Term Debt Issued | - | 625.01 | 193.13 | - | 291 | 20 |
Total Debt Issued | 675.01 | 705.01 | 272.13 | 224 | 538 | 73 |
Short-Term Debt Repaid | - | -160 | -56 | -288.03 | -178.97 | -122 |
Long-Term Debt Repaid | - | -605.21 | -122.33 | -91.64 | -118.66 | -154.6 |
Total Debt Repaid | -652.87 | -765.21 | -178.33 | -379.67 | -297.63 | -276.6 |
Net Debt Issued (Repaid) | 22.13 | -60.21 | 93.8 | -155.67 | 240.37 | -203.6 |
Issuance of Common Stock | 0.02 | 238.22 | - | 61.48 | 143.64 | - |
Common Dividends Paid | -153.17 | -153.17 | -95.63 | -29.75 | -9.77 | -22.36 |
Other Financing Activities | - | - | - | - | -0.02 | - |
Financing Cash Flow | -131.02 | 24.85 | -1.83 | -123.94 | 374.22 | -225.96 |
Net Cash Flow | -64.71 | 62.74 | 80.28 | -6.03 | -10.79 | 9.35 |
Free Cash Flow | 119.01 | 100.56 | 108.06 | 117.13 | -379.09 | 216.43 |
Free Cash Flow Growth | 0.15% | -6.94% | -7.75% | - | - | - |
Free Cash Flow Margin | 10.41% | 9.06% | 10.90% | 12.45% | -36.60% | 25.73% |
Free Cash Flow Per Share | 2.48 | 2.16 | 2.59 | 2.85 | -12.46 | 7.70 |
Cash Interest Paid | 13.84 | 13.84 | 14.94 | 13.6 | 6.42 | 6.31 |
Cash Income Tax Paid | 47.12 | 47.12 | 43.1 | 51.74 | 28.44 | 11.83 |
Levered Free Cash Flow | 29.83 | 49.38 | 67.88 | 106.57 | -412.67 | - |
Unlevered Free Cash Flow | 36.68 | 54.39 | 71.51 | 110.13 | -410.04 | - |
Change in Working Capital | -53.53 | -20.19 | 7.12 | -5.95 | 4.56 | 1.7 |